Project Grant R41CA298754
Award Date
2/1/25
Completion Date
1/31/26
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Awardee
Argosmd, Inc. (GZUUVCTL4U89)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This National Cancer Institute (NCI) Project Grant award under CFDA 93.394 "Cancer Detection and Diagnosis Research" is supporting the development of a portable, battery-powered, closed-loop cryotherapy system called the CRCL System. The $1,172,978 award to Ananya Health Inc. aims to create an affordable and effective treatment option for cervical precancerous lesions in low- and middle-income countries (LMICs). The key product deliverables include finalizing the CRCL System design,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) provides $391,325 to the University of Arizona to develop a new portable confocal microscope (PCM) device and evaluate its clinical utility for assessing chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. The objectives are to: 1) develop a new PCM device enabling rapid, repeatable imaging of mechanoreceptors (Meissner's corpuscles) associated with CIPN, 2)...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development and evaluation of an Electrical Impedance Dermography (EID) technology to improve the diagnosis and management of non-melanoma skin cancers. The $349,878 award, effective January 1, 2025 through December 31, 2026, will enable researchers at the University of Utah to collect EID data on 120 subjects with lesions clinically...
This $962,560 Project Grant (R01CA285369) awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMICs). The key products and services to be delivered under this grant include: 1) Modifying the existing IRISTM prototype to include...
This $2,020,098 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop an innovative X-ray dual-energy cone-beam microCT (DECB microCT) imaging system for intraoperative quantitative analysis of breast lumpectomy specimens. The objective is to enhance the contrast between breast cancer and normal fibroglandular tissue, enabling improved identification of positive surgical margins during breast-conserving surgery. Key project...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $671,072 to the University of Washington to develop a novel miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from cancer patient samples. The multidisciplinary project aims to leverage micro- and nano-fabrication techniques to create an...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to O2M Technologies LLC, a small for-profit corporation, to develop a Multifunctional Imager (MFI) capable of simultaneously generating 3D maps of tissue oxygen pressure (pO2) and pH. The goal of this 1-year project is to create an advanced electron paramagnetic resonance imaging (EPRI) instrument that can perform both pulse and continuous wave...
The National Cancer Institute (NCI) awarded a $1,729,890 Cooperative Agreement under the Cancer Treatment Research program (CFDA 93.395) to The Washington University to develop and validate a new medical imaging technology called SkinScan3D (SS3D) for improving Kaposi Sarcoma (KS) treatment monitoring in East Africa. The project aims to refine the SS3D device, which combines liquid lens technology and AI, to provide high-resolution 3D imaging of KS lesions to more accurately assess treatment...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a real-time functional imaging platform to detect and characterize prostate cancer aggressiveness. The $568,151 award, effective from February 3, 2025 to January 31, 2030, will enable the Regents of the University of Michigan to: Optimize biocompatible polyacrylamide hydrogel nanoscale probes (PAA NPs) for...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support the development of a "laser microbiopsy" technique to harvest micro-sized tissue samples for melanoma diagnosis and analysis. The University of Texas at Austin is the prime awardee, receiving $203,610 over the project period from August 2024 to July 2027. The key objectives are to refine and characterize the performance of the laser microbiopsy hardware...